Tier 3 — preclinical

NAD + supplementation normalizes key Alzheimer's features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency

Hou Y, Lautrup S, Cordonnier S, Wang Y, Croteau DL, Zavala E, Zhang Y, Moritoh K, O'Connell JF, Baptiste BA, Stevnsner TV, Mattson MP, Bohr VA

Proceedings of the National Academy of Sciences of the United States of America 2018 115; 8; E1876-E1885

Bibliography

PubMed: PMID 29432159
PubMed Central: PMC5828618
DOI: 10.1073/pnas.1718819115
Funding: Indexed grant support includes NIA NIH HHS. The complete funding declaration is not specified in the accessible abstract.
Competing interests: The authors reported no competing interests.

Design	Preclinical animal study with supporting assays as applicable
Model	Transgenic mouse models
Sample	Transgenic Alzheimer’s and DNA-repair-deficient mice
Intervention	NR supplementation
Duration	Model-specific intervention and behavioral testing
Endpoints	Model-specific physiological outcomes; Biochemical or functional measures reported in the study

NR improved selected tau, DNA-damage, inflammatory and behavioral measures in the tested Alzheimer’s mouse models.

NR improved selected tau, DNA-damage, inflammatory and behavioral measures in the tested Alzheimer’s mouse models.

Amyloid accumulation was not reduced, and these experiments do not establish cognitive efficacy in humans.

Editorial review

Last verified 22 October 2026